AI
| Followers | 3 |
| Posts | 3535 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2005 |
Wednesday, December 01, 2010 5:22:56 PM
Gold, Maybe you can add this test to your DRE. They look to be of the same caliber.
Prostate Cancer Risk Is Lower in Men With Long Index Fingers, Study Finds
By Marthe Fourcade - Nov 30, 2010 7:01 PM ET
inShare.1More
Men with long index fingers are at lower risk of prostate cancer, a study found.
Scientists in the U.K. who compared the hands of 1,500 prostate cancer patients and 3,000 healthy men found that those whose index was longer than their ring finger were 33 percent less likely to develop the potentially fatal disease.
“Relative finger length could be used as a simple test for prostate cancer risk,” said Ros Eeles, one of the study’s lead authors and a researcher who investigates links between genetic makeup and tumors at London’s Institute of Cancer Research, in a statement. The study was published in the British Journal of Cancer today.
Finger length is set before birth, influenced by the level of sex hormones babies are exposed to in the womb, researchers from the ICR and the University of Warwick in Coventry, England, said in the statement. A longer index finger points to less testosterone, which may protect against cancer later in life, they said.
“Our study indicates it is the hormone levels that babies are exposed to in the womb that can have an effect decades later,” Ken Muir of the University of Warwick, the study’s other lead author, said in the statement. “As our research continues, we will be able to look at a further range of factors that may be involved in the makeup of the disease.”
Scientists from Johns Hopkins University School of Medicine and the U.S. National Institute of Aging in 2004 found that men with high blood levels of testosterone were at increased risk of prostate cancer.
In the study published today, more than half of the men had an index shorter than the ring finger. Those whose two fingers were about equal had a similar prostate cancer risk, the researchers found.
Prostate Action and Cancer Research UK funded the study.
To contact the reporter on this story: Marthe Fourcade at mfourcade@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
.
Prostate Cancer Risk Is Lower in Men With Long Index Fingers, Study Finds
By Marthe Fourcade - Nov 30, 2010 7:01 PM ET
inShare.1More
Men with long index fingers are at lower risk of prostate cancer, a study found.
Scientists in the U.K. who compared the hands of 1,500 prostate cancer patients and 3,000 healthy men found that those whose index was longer than their ring finger were 33 percent less likely to develop the potentially fatal disease.
“Relative finger length could be used as a simple test for prostate cancer risk,” said Ros Eeles, one of the study’s lead authors and a researcher who investigates links between genetic makeup and tumors at London’s Institute of Cancer Research, in a statement. The study was published in the British Journal of Cancer today.
Finger length is set before birth, influenced by the level of sex hormones babies are exposed to in the womb, researchers from the ICR and the University of Warwick in Coventry, England, said in the statement. A longer index finger points to less testosterone, which may protect against cancer later in life, they said.
“Our study indicates it is the hormone levels that babies are exposed to in the womb that can have an effect decades later,” Ken Muir of the University of Warwick, the study’s other lead author, said in the statement. “As our research continues, we will be able to look at a further range of factors that may be involved in the makeup of the disease.”
Scientists from Johns Hopkins University School of Medicine and the U.S. National Institute of Aging in 2004 found that men with high blood levels of testosterone were at increased risk of prostate cancer.
In the study published today, more than half of the men had an index shorter than the ring finger. Those whose two fingers were about equal had a similar prostate cancer risk, the researchers found.
Prostate Action and Cancer Research UK funded the study.
To contact the reporter on this story: Marthe Fourcade at mfourcade@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
